A provider-focused update on Winlevi (Clascoterone) availability in 2026. Covers supply status, prescribing implications, cost landscape, and patient access strategies.
Winlevi (Clascoterone) cream 1% remains the only FDA-approved topical androgen receptor inhibitor for acne vulgaris. Since its approval in August 2020, it has offered prescribers a novel mechanism of action for patients who haven't responded adequately to conventional topical therapies. However, real-world accessibility continues to present challenges that directly affect prescribing decisions and patient outcomes.
This briefing covers the current supply landscape, prescribing considerations, and actionable strategies to help your patients access Winlevi.
A brief overview of key milestones:
Winlevi's unique mechanism — topical androgen receptor blockade — fills a gap in the acne treatment algorithm that no other topical agent addresses. Key clinical considerations:
Mechanism of action: Clascoterone competitively inhibits androgen receptors in sebocytes and hair follicles. In vitro, it demonstrates greater efficacy than Spironolactone and Enzalutamide at the androgen receptor. Importantly, systemic absorption is minimal, resulting in negligible systemic antiandrogenic effects.
Efficacy data: Two Phase III trials (N=1,421) demonstrated treatment success in 18-20% of Clascoterone-treated patients vs. 7-9% with vehicle, over 12 weeks. Acne symptom reduction was 8-18% greater than placebo.
Safety profile: Local skin reactions (erythema, scaling/dryness, pruritus) are the most common adverse effects and occur at rates similar to vehicle. HPA axis suppression was observed in 7% of tested subjects but was reversible within 4 weeks of discontinuation. Hyperkalemia was observed in 5% vs. 4% with placebo. Reproductive effects (polycystic ovaries, amenorrhea) have been noted in post-market surveillance.
Patient selection: Winlevi is particularly relevant for patients with hormonal acne patterns who prefer topical therapy, male patients who cannot use Spironolactone, and patients who have failed or cannot tolerate retinoids. It can be used as monotherapy or in combination with other topical agents.
Despite adequate manufacturing supply from Sun Pharmaceutical, pharmacy-level availability remains problematic:
Cost remains a significant barrier to patient access:
The lack of a generic option means that cost will likely remain a primary barrier until patent expiration.
Several resources can help you and your patients navigate Winlevi access:
Medfinder for Providers — A free platform that helps locate pharmacies with Winlevi in stock in real time. You can recommend this tool directly to patients or use it within your practice to identify the nearest stocked pharmacy before the patient leaves your office.
Prior authorization support: Having a standardized PA letter template that documents the patient's acne severity, previous treatments tried, and clinical rationale for Winlevi can expedite the approval process.
Samples: If available through your Sun Pharmaceutical representative, starter samples can bridge the gap while patients navigate insurance and pharmacy logistics.
Pharmacy partnerships: Establishing relationships with one or two pharmacies (especially independent or specialty pharmacies) that reliably stock Winlevi can streamline the fill process for your entire patient panel.
Several developments may affect Winlevi's landscape in the coming years:
Winlevi fills a genuine unmet need in acne management, but access barriers remain significant in 2026. Proactive prescribing — including pharmacy selection guidance, PA preparation, and cost navigation — can meaningfully improve your patients' ability to access this medication.
For a patient-facing overview of availability issues, you can share our article: Winlevi shortage update for patients. For guidance on helping patients find the medication, see our provider's guide to helping patients find Winlevi.
Visit Medfinder for Providers to access real-time availability tools for your practice.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
